Preimplantation Genetic Testing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Afric

The global preimplantation genetic testing (PGT) market is experiencing rapid growth, primarily fueled by technological advancements in genetic screening and the increasing prevalence of infertility worldwide. PGT, which involves screening embryos created through in-vitro fertilization (IVF) for genetic abnormalities before implantation, is becoming an integral part of assisted reproductive technology (ART). The market is forecast to grow from US$0.74 billion in 2025 to US$1.59 billion by 2032, registering a strong compound annual growth rate (CAGR) of 10.47%.

Market Insights

The expansion of the PGT market is underpinned by growing awareness of genetic disorders and the rising demand for healthy pregnancies. More couples are turning to IVF and PGT as fertility treatments due to increased maternal age and lifestyle changes that impact reproductive health. Innovations in genetic testing methods, particularly the integration of next-generation sequencing (NGS), polymerase chain reaction (PCR), and fluorescence in-situ hybridization (FISH), have significantly improved the accuracy and reliability of PGT.

The increasing adoption of PGT is also linked to its ability to screen embryos for inherited disorders, chromosomal abnormalities, and aneuploidy. These capabilities help reduce the risk of failed pregnancies and birth defects, making PGT a vital option for couples with known genetic risks.

Market Drivers

Advancements in Genetic Testing Technologies

One of the primary growth drivers is the continuous innovation in genetic testing. Technologies such as NGS and CRISPR have enhanced the precision and scope of embryo screening. These advancements enable the detection of multiple gene variants in a single test, providing more detailed insights into the embryo’s genetic profile.

Rising Infertility and Delayed Parenthood

Infertility rates continue to rise globally due to lifestyle factors, environmental stressors, and delayed family planning. As more individuals choose to conceive later in life, the need for comprehensive genetic testing during fertility treatments becomes more critical. PGT supports this demand by increasing the likelihood of successful pregnancies, especially for older women or those with a history of genetic conditions.

Increased Public Awareness and Acceptance

Awareness campaigns, media exposure, and improved access to fertility services have increased public knowledge and acceptance of PGT. As the social stigma surrounding fertility treatments diminishes, more couples are open to exploring PGT as a means to ensure healthy offspring. Genetic counseling services are also playing a vital role in guiding patients through the testing process.

Business Opportunities

Personalized Medicine and Precision Health

The alignment of PGT with the broader trend of personalized medicine presents significant opportunities for market players. Personalized medicine focuses on tailoring medical treatments based on individual genetic profiles, and PGT fits seamlessly into this model. It allows for embryo selection based on genetic compatibility and disease prevention, offering a high degree of personalization in reproductive health.

AI and Machine Learning Integration

The integration of artificial intelligence and machine learning in genetic testing is opening new avenues for innovation. These technologies help in analyzing vast datasets quickly and accurately, which improves the efficiency and effectiveness of PGT. As these tools become more accessible, they are expected to boost the adoption of PGT among fertility clinics and healthcare providers.

Expansion into Emerging Markets

With improving healthcare infrastructure and growing awareness, emerging markets in Asia Pacific, Latin America, and the Middle East offer untapped growth potential. Manufacturers and service providers are focusing on these regions to expand their reach and offer more affordable and accessible PGT solutions.

Regional Analysis

North America leads the global PGT market, driven by high healthcare spending, the presence of advanced fertility clinics, and favorable regulatory frameworks. The region benefits from a large number of ART centers offering genetic testing as part of their IVF services. States such as Massachusetts, New Jersey, and California are particularly advanced in providing ART procedures.

Europe follows closely behind, supported by robust public health systems, government-funded fertility programs, and increasing demand for ART. Meanwhile, Asia Pacific is emerging as a promising region, with rising disposable incomes, growing awareness, and investments in reproductive healthcare.

Key Players

The PGT market is highly competitive, with several global players focusing on technological innovation and strategic partnerships. Key players include:
• Illumina, Inc. – A leader in genomics, offering a wide range of NGS-based solutions for PGT.
• Thermo Fisher Scientific Inc. – Known for developing research instruments specifically for PGT-A testing.
• Natera, Inc. – A prominent player offering non-invasive and highly accurate genetic testing solutions.
• CooperSurgical, Inc. – Specializes in fertility and genomics with a comprehensive portfolio in PGT.
• PerkinElmer, Inc. – Provides diagnostic solutions supporting precision medicine in reproductive health.

Other notable companies include Quest Diagnostics Incorporated, Invitae Corporation, Laboratory Corporation of America Holdings, Genea Pty Limited, Bioarray S.L., Igenomix, RGI, and F. Hoffmann-La Roche Ltd.

These players are actively involved in product innovation, mergers and acquisitions, and partnerships with IVF clinics to strengthen their market presence.

Recent Developments

In January 2024, Orchid Health introduced a commercially available solution for whole-genome sequencing in preimplantation embryos, enabling targeted screening for specific inherited diseases.

In July 2023, Thermo Fisher Scientific unveiled two new research-use-only NGS instruments designed for PGT-A, enhancing capabilities in IVF and ICSI procedures.

These developments highlight the industry’s focus on offering high-precision, user-friendly genetic testing platforms to improve IVF success rates and patient outcomes.

Market Segmentation

By Procedure
• Genetic Diagnosis
• Genetic Screening

By Product
• Reagents
• Instruments

By Technology
• Next Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Fluorescent In-Situ Hybridization (FISH)

By Region
• North America
• Latin America
• Europe
• Asia Pacific
• The Middle East & Africa

Please note: Delivery Timelines - 5 working days.